Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jennifer D. Bright"'
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
Cancer immunotherapy is a powerful tool for inducing antigen-specific antitumor cytotoxic T lymphocytes (CTLs). Next-generation strategies may include vaccination against overexpressed oncogenic tumor-self antigens. Previously, we reported vaccinatio
Externí odkaz:
https://doaj.org/article/e7a79d26094148eead68089850eccb11
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 6, Pp 1413-1423 (2020)
Development of cancer vaccines targeting tumor self-antigens is complex and challenging due to the difficulty of overcoming immune tolerance to self-proteins. Vaccination against tumor self-protein D52 (D52) has been successful, although complete pro
Externí odkaz:
https://doaj.org/article/6227b90d0a4b424cb2ae56a691ac0db6
Publikováno v:
Hum Vaccin Immunother
Development of cancer vaccines targeting tumor self-antigens is complex and challenging due to the difficulty of overcoming immune tolerance to self-proteins. Vaccination against tumor self-protein D52 (D52) has been successful, although complete pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09df74ed9d33736b67dbc9748bbc76b5
https://pubmed.ncbi.nlm.nih.gov/31769704
https://pubmed.ncbi.nlm.nih.gov/31769704
Publikováno v:
Human Vaccines & Immunotherapeutics. 10:3297-3305
Overexpressed tumor-self antigens represent the largest group of candidate vaccine targets. Those exhibiting a role in oncogenesis may be some of the least studied but perhaps most promising. This review considers this subset of self antigens by high
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78c8861579f0c4b2639f5e4580ad73b5
https://doi.org/10.4161/hv.29475
https://doi.org/10.4161/hv.29475
Publikováno v:
Oncoimmunology
Tumor protein D52 (D52) is constitutively expressed in healthy tissues and overexpressed in multiple cancers, including (but not limited to) breast, prostate and ovarian carcinomas. Although the normal functions of D52 are unknown, it is clear that i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::171e5abefac5a3f1bcd12470f8c36499
https://doi.org/10.4161/onci.25049
https://doi.org/10.4161/onci.25049
Publikováno v:
Cancer Research. 70:4791-4791
Tumor protein D52 (TPD52) is a novel auto-antigen involved in cellular transformation, proliferation and metastasis. Its over-expression has been demonstrated in several human malignancies including prostate, breast, and ovarian carcinomas. Murine TP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a97ecba91137f1c13126856fbd65a7f
https://doi.org/10.1158/1538-7445.am10-4791
https://doi.org/10.1158/1538-7445.am10-4791